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Abstract
Niacin, as an antidyslipidemic drug, elicits a strong flushing
response by release of prostaglandin (PG) D2. However, whether
niacin is beneficial for inflammatory bowel disease (IBD) remains
unclear. Here, we observed niacin administration-enhanced PGD2
production in colon tissues in dextran sulfate sodium (DSS)-chal-
lenged mice, and protected mice against DSS or 2,4,6-trinitroben-
zene sulfonic acid (TNBS)-induced colitis in D prostanoid receptor 1
(DP1)-dependent manner. Specific ablation of DP1 receptor in
vascular endothelial cells, colonic epithelium, and myeloid cells
augmented DSS/TNBS-induced colitis in mice through increasing
vascular permeability, promoting apoptosis of epithelial cells, and
stimulating pro-inflammatory cytokine secretion of macrophages,
respectively. Niacin treatment improved vascular permeability,
reduced apoptotic epithelial cells, promoted epithelial cell update,
and suppressed pro-inflammatory gene expression of macrophages.
Moreover, treatment with niacin-containing retention enema
effectively promoted UC clinical remission and mucosal healing in
patients with moderately active disease. Therefore, niacin
displayed multiple beneficial effects on DSS/TNBS-induced colitis in
mice by activation of PGD2/DP1 axis. The potential efficacy of niacin
in management of IBD warrants further investigation.
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Introduction
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD)
characterized by recurrent episodes of active disease, which
commonly affects the colon, the rectum, or both simultaneously.
Histologically, it displays chronic inflammatory alterations limited to
the mucosa and submucosa with cryptitis and crypt abscesses
(Danese & Fiocchi, 2011). Despite UC-related mortality being low, its
morbidity remains high and 10–20% of affected individuals undergo
colectomy. Although the UC etiology is largely unknown, accumu-
lated evidence supports an interaction between genetic predisposi-
tion and microbial/environmental factors that trigger pro-colitogenic
perturbations of the host–commensal relationship and an aberrant
mucosal immune response (Khor et al, 2011). Genome-wide associa-
tion studies (GWAS) have identified 47 genetic susceptibility loci for
UC, 28 of which are shared between Crohn’s disease (CD) and UC
(Franke et al, 2010; Anderson et al, 2011). Indeed, these risk loci
implicated in IBD are involved in different key signal pathways
which are essential for intestinal homeostasis, such as epithelial
restitution, barrier function, innate and adaptive immune regulation,
microbial defense, cellular stress, and metabolism (Khor et al,
2011). Moreover, vascular injury including dilated vessels and
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increased vascular permeability also contributes to the inflammatory
disorder of colonic mucosa in UC patients (Deng et al, 2013).
Niacin (nicotinic acid) is also known as vitamin B3 and serves as a
precursor for coenzymes such as nicotinamide adenine dinucleotide
(NAD) and nicotinamide adenine dinucleotide phosphate (NADP),
which are essential for living cells. Niacin has been used for more
than five decades to treat dyslipidemia, because it reduces low-
density lipoprotein cholesterol (LDLc), very low-density lipoprotein
cholesterol (VLDLc), and triglycerides (TGs), and elevates high-
density lipoprotein cholesterol (HDLc) (Song & FitzGerald, 2013). The
orphan G-protein-coupled receptor GPR109A, also known as hydroxy-
carboxylic acid 2 (HCA2) in mice, and as HM74A in humans, can be
activated by niacin (Wise et al, 2003). The beneficial effect of niacin
on free fatty acid and TGs is mediated by GPR109A suppression of
lipolysis; however, the effects on HDLc and LDLc are not mediated by
the GPR109A receptor (Bodor & Offermanns, 2008). GPR109A expres-
sion is markedly upregulated in macrophages upon inflammatory
stimulation (Feingold et al, 2014). Moreover, emerging evidence
demonstrated that niacin displays multiple anti-inflammatory
properties through GPR109A receptor activation (Holzhauser et al,
2011; Digby et al, 2012; Godin et al, 2012; Zandi-Nejad et al, 2013;
Zhou et al, 2014). Thus, the potential therapeutic efficacy of niacin
on patients with UC warrants further clinical investigation.
One unpleasant side effect caused by niacin is cutaneous flushing.
Niacin stimulates prostaglandin D2 (PGD2) release in both mice and
humans (Hanson et al, 2010; Song & FitzGerald, 2013), which plays
a central role in the niacin-induced flushing. Low-dose aspirin could
depress niacin-evoked PGD2 release and reduce the associated
flushing (Cefali et al, 2007; Song & FitzGerald, 2013). PGD2
promotes the niacin-evoked flushing through its specific D prosta-
noid receptor 1 (DP1). Blockade of DP1 receptor completely inhibits
niacin-induced vasodilation in mice and humans without affecting
its effects on lipid metabolism (Cheng et al, 2006; Paolini et al, 2008;
Maccubbin et al, 2009). In addition, PGD2 mediates active resolution
of inflammation through DP1 receptor (Rajakariar et al, 2007; Kong
et al, 2016). Interestingly, marked elevation of PGD2 production was
observed in inflamed colon tissues from both UC patients and experi-
mental colitis murine models (Ajuebor et al, 2000; Vong et al, 2010),
which is associated with long-term remission in humans (Vong et al,
2010). Yet, it remains to be determined whether niacin-mediated
protection against UC depends on PGD2 production.
In this study, we investigated the therapeutic effect of niacin on
colitis both in mice and in patients with moderately active UC. We
found that niacin shows anti-inflammatory and anti-apoptotic
properties through downregulation of colonic inflammatory cytokine
levels, suppression of vascular permeability, and inhibition of colonic
epithelium apoptosis by activation of DP1 receptor in macrophages,
endothelial cells, and colonic epithelium. Furthermore, treatment
with retention enema containing niacin effectively promoted clinical
remission and mucosal healing in patients with moderately active UC.
Results
Niacin boosts PGD2 generation in mice
To explore whether niacin protects against inflammatory bowel
diseases (IBDs) through releasing PGD2, we first examined
niacin-induced PGD2 production in colon tissues and urinary secre-
tion of PGD2 metabolites- 11,15-Dioxo-9a-hydroxy-2,3,4,5-tetranor-
prostan-1,20-dioic acid (tetranor PGDM) from DSS-induced colitis
mouse model by using mass spectrometry analysis. Indeed, PGD2
production in homogenized colons and urinary tetranor PGDM was
markedly elevated by niacin administration in DSS-challenged mice
in a dose-dependent manner (Fig 1A and B). In addition, niacin
treatment induced PGF2a product in colon tissues (Fig EV1A) and
increased urinary metabolites of PGE2, PGI2, and PGF2a (Fig EV1B)
in DSS-challenged mice, indicating niacin may upregulate PG
biosynthesis pathway. Accordingly, we observed niacin treatment
upregulated cytosolic phospholipase A2 (cPLA2), COX-2, and
hematopoietic PGD synthase (hPGDS) in peritoneal macrophages
(Fig 1C–E). However, niacin had no markedly influence on special-
ized pro-resolving mediators (SPMs) in colon tissues from DSS-
challenged mice, such as lipoxin (LX) A4, resolvin (Rv) E1
(Fig EV1C).
Disruption of DP1 receptor deteriorates both DSS- and
TNBS-induced colitis in mice
PGD2 specifically binds and activates two distinct D prostanoid
receptors DP1 and DP2. Next, we investigated the effects of PGD2
receptor deficiency on development of DSS- or TNBS-induced colitis
in mice. Interestingly, mice with global DP1 disruption (Fig 2A) lost
over 12% more weight than wild-type (WT) controls (Fig 2B), and
had significantly higher DAI than WT after DSS challenge
(2.33  0.33 vs. 0.42  0.22, P < 0.01, Fig 2C). Accordingly, DP1
deletion augmented the severity of DSS-induced colitis in mice
including reduction of colon length (Fig 2D), increase of epithelial
cell lost, thickening of intestinal wall, enhanced infiltration of
inflammatory cells in colon tissues (Fig 2E), and increase of overall
mortality (Fig 2F). Likewise, DP1/ mice were also more vulnera-
ble to TNBS-induced colitis (Fig EV2). However, DP2 deficiency
(Satoh et al, 2006) did not influence DSS-induced colitis in mice
(Fig 2A–F). Thus, activation of DP1 receptor, not DP2, protects mice
against DSS/TNBS-induced colitis.
Niacin ameliorates DSS/TNBS-induced colitis in mice through
DP1 receptor
Treatment with niacin promotes PGD2 release in colon tissues
(Fig 1A), and disruption of DP1 receptor worsens DSS/TNBS-
induced colitis in mice (Figs 2 and EV2). We hypothesized niacin
could improve clinical manifestation of colitis induced by DSS or
TNBS. Indeed, administration of niacin (600 mg/kg by gavage, once
a day, Fig 3A) markedly delayed body weight loss (7.94  1.44%
vs. 14.25  1.03%, P < 0.01, Fig 3B), elevation of DAI (1.46  0.14
vs. 2.58  0.16, P < 0.01, Fig 3C), and shortening of colon length
(6.26  0.19 cm vs. 4.43  0.27 cm, P < 0.01, Fig 3D and E)
caused by DSS challenge in WT mice, and consequently reduced
mortality (Fig 3F). In addition, niacin also ameliorated body weight
loss and shortening of colon length caused by TNBS challenge in
mice (Fig EV3). In contrast, these beneficial effects of niacin were
not observed in DP1-deficient mice (Figs 3B–F and EV3).
We also examined the effect of niacin on oxidative stress and
plasma lipids in mice. As shown in Appendix Fig S1, the levels of
8-isoprostane PGF2a in colon tissues and urine were not altered
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Figure 1. Niacin induces PGD2 secretion in DSS-challenged mice.
A Mass spectrometry analysis of PGD2 production in colons from niacin-treated mice after DSS challenge.
B Mass spectrometry analysis of urinary PGD2 metabolites (PGDM) from niacin-treated mice after DSS challenge. PGDM, 11,15-dioxo-9 alpha-hydroxy-2,3,4,5-
tetranorprostan-1,20-dioic acid.
C–E Real-time PCR analysis of cPLA2, COX-1, COX-2, and hPGDS expression in peritoneal macrophage treated with niacin.
Data information: Data are shown as mean  SEM. Data are representative of at least two independent experiments. Statistical significance was determined using
unpaired Student’s t-tests. (A) #P < 0.05, ##P < 0.01 vs. vehicle; vehicle, n = 6; niacin 300 mg/kg, n = 5; niacin 600 mg/kg, n = 7. (B) #P < 0.05, ##P < 0.01 vs. vehicle;
n = 6. (C–E) #P < 0.05 vs. vehicle; n = 4.
ª 2017 The Authors EMBO Molecular Medicine Vol 9 | No 5 | 2017
Juanjuan Li et al Niacin therapy for UC EMBO Molecular Medicine
573
Published online: March 24, 2017 
0 2 4 6 8 10
0
25
50
75
100
Days
P
er
ce
nt
 s
ur
vi
va
l
WT
DP1-/- *
A 
C 
WT 
 KO 
WT DP1-/- 
 WT 
 KO 
WT DP2-/- 
284bp
300bp
F 
344bp
250bp
B 
D 
0
2
4
6
8
WT
DP2-/-
E DP1-/- WT 
DP2-/- WT 
0 2 4 6 8 10
0
25
50
75
100
Days
WT
DP2-/-
0
2
4
6
8
C
ol
on
 le
ng
th
(c
m
)
**
WT
DP1-/-
2 4 6
-1
0
1
2
3
Days 
D
A
I
WT
DP1-/-
**
**
**
2 4 6
-5
0
5
10
15
Days B
od
y 
w
ei
gh
t l
os
s(
%
)
WT
DP1-/-
**
**
DP1-/- WT WT DP2-/- 
2 4 6
-5
0
5
10
15 WT
DP2-/-
Days
2 4 6
-1
0
1
2
3
Days
WT
DP2-/-
Figure 2. DP1 knockout augments DSS-induced colitis in mice.
A PCR analysis of tail genomic DNA from DP1/, DP2/, and WT mice.
B–D Body weight loss (B) and disease activity index (C), and colon length (D) of DP1/, DP2/, and WT mice in response to DSS challenge. Scale bar: 1 cm.
E H&E staining of histological sections in the distal colon from the mice administered with DSS for 6 days. Scale bars: 100 lm. Graphs represent overall histology
score.
F Survival rates of DSS-challenged DP1/, DP2/ mice, and WT controls.
Data information: Data are shown as mean  SEM. Data are representative of three independent experiments. (B–D) Statistical significance was determined using
unpaired Student’s t-tests. **P < 0.01 compared with WT. Left panel: WT, n = 8; DP1/, n = 8. Right panel: WT, n = 7; DP2/, n = 8. (F) Survival rate was compared
using the log-rank test. *P < 0.05, compared with WT; n = 10.
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Figure 3. Niacin protects mice from DSS-induced colitis.
A Protocol for niacin treatment on DSS-induced colitis in mice.
B, C Effect of niacin treatment on body weight loss (B) and disease activity index (C) of DP1/ and WT mice in response to DSS challenge.
D Macroscopic appearance of colons from DSS-challenged mice after niacin treatment. Scale bar: 1 cm.
E Effect of niacin treatment on colon length (centimeter) of DP1/ and WT mice in response to DSS challenge.
F Effect of niacin treatment on survival rates of DSS-challenged DP1/ mice and WT controls.
Data information: Data are representative of two independent experiments. (B, C, E) Data are shown as mean  SEM. Statistical analysis was performed using unpaired
Student’s t-test. #P < 0.05, ##P < 0.01 vs. vehicle; n = 8. (F) Survival rate was compared using the log-rank test. #P < 0.05, vs. vehicle, *P < 0.05, **P < 0.01 compared
with WT; WT, n = 17; DP1/, n = 20.
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(Appendix Fig S1A) by niacin treatment in mice, while plasma
cholesterol and triglyceride were markedly decreased after niacin
treatment (Appendix Fig S1B).
DP1 deletion in vascular endothelial cells, epithelial cells, and
myeloid cells, but not in smooth muscle cells, exacerbates the
development of DSS/TNBS-induced colitis in mice
DP1 receptor is expressed in colon tissues from healthy subjects,
but its downregulation was detected in patients with active colitis
(Vong et al, 2010). To determine which cell types express DP1
receptor, we performed double immunofluorescence staining of DP1
and different cell type-specific markers in inflamed colon tissues
from both UC patients and DSS-challenged mice. Sections were
stained for DP1 along with a a-actin, a smooth muscle cell (SMA)-
specific marker, CD31, an endothelial cell marker, pan-keratin, an
epithelial cell marker, or CD68, a macrophage marker. Doubly
stained cells were observed among all these marker positive cells
(Fig 4A and B), indicating DP1 was expressed variably in multiple
cell types including smooth muscle cells, vascular endothelial cells,
colonic epithelial cells, and macrophages.
To identify the cell types in which loss of DP1 function exaggerated
the murine colitis, DP1Flox/Flox (DP1F/F) mice were crossed with
Tie2Cre, VillinCre, LysMCre, or SM22Cre transgenic mice to generate
vascular endothelial cell, colonic epithelial cell, macrophage, or
smoothmuscle cell-specific DP1-deficient mice, respectively (Fig 4C).
Since Tie2 kinase is also expressed in hematopoietic progenitors
(Zhou et al, 2009), DP1 downregulation (~22%) in colonic macro-
phages was detected in DP1F/F/Tie2Cre mice (data not shown). As
shown in Figs 4D–F and EV4A, DP1F/F/Tie2Cre, DP1F/F/VillinCre, and
DP1F/F/LysMCre mice displayed considerably more body weight loss
(Figs 4D and EV4A), higher DAI (Figs 4E and EV4A), and shorter
colon (Figs 4F and EV4A) after DSS or TNBS challenge, as compared
to DP1F/F mice. In contrast, DP1F/F/SM22Cre mice did not differ from
control mice in response to DSS or TNBS challenge (Figs 4D–F and
EV4A). Together, these results suggest that DP1 receptor in the vascu-
lar endothelial cells, epithelial cells, and myeloid cells may mediate
protective effects against DSS/TNBS-induced colitis in mice.
Niacin suppresses vascular permeability in experimental colitis
Endothelial damage, increased colonic vascular permeability,
perivascular edema, and subsequent epithelial hypoxia are essential
for the development of ulcerative colitis (Deng et al, 2013).
Deletion of DP1 receptor in vascular endothelial cells exacerbated
DSS-induced colitis in mice including aggravated perivascular
edema and enhanced infiltration of inflammation cells (Fig 5A). In
the ear model of LPS-evoked vascular permeability, endothelial cell
deficiency of DP1 significantly augmented leakage as measured by
Evan’s blue dye extravasation (A610: 0.27  0.01 vs. 0.21  0.01,
P < 0.01, Fig 5B and C). Administration of DP1 agonist BW245C
(3 mg/kg by subcutaneous injection) markedly inhibited LPS-trig-
gered vascular permeability in DP1F/F mice (A610: 0.10  0.01 vs.
0.21  0.01, P < 0.01, Fig 5B and C) but not in DP1F/F/Tie2Cre
mice (Fig 5B and C). Consistent with this observation, more extra-
vasated Evan’s blue in colonic tissues was observed in DSS- or
TNBS-challenged DP1F/F/Tie2Cre mice than DP1F/F controls
(0.26  0.02 lg/mg vs. 0.11  0.01 lg/mg, P < 0.01, Fig 5D;
0.23  0.01 lg/mg vs. 0.11  0.01 lg/mg, P < 0.01 Fig EV4B).
The administration of niacin reduced Evan’s blue extravasation in
the inflamed intestines at both day 6 (0.10  0.01 lg/mg vs.
0.13  0.01 lg/mg, P = 0.06) and day 9 (0.14  0.02 lg/mg vs.
0.26  0.03 lg/mg, P < 0.01, Fig 5E). This reduction of vascular
permeability was entirely blocked by DP1 deletion in vascular
endothelial cells (Fig 5E), indicating niacin inhibits vascular perme-
ability in intestinal tissues through activation of PGD2/DP1 signal
in endothelial cells.
Niacin suppresses apoptosis of intestinal epithelial cells in
experimental colitis in mice
Intestinal epithelium barrier breakdown is a hallmark of colitis.
Increased apoptosis and decreased proliferation contribute to a break-
down of the epithelial barrier function in DSS-induced colitis (Araki
et al, 2010). Indeed, DP1 deletion in intestinal epithelium (DP1F/F/
VillinCre) resulted in greater crypt and epithelial cell loss in mice with
DSS-induced colitis as compared with DP1F/F mice (Fig 6A). TUNEL
staining clearly showed higher frequency of apoptotic epithelial cells
in DSS- or TNBS-challenged DP1F/F/VillinCre mice than in control
mice (54.75  4.99 cells/field vs. 24.80  1.66 cells/field, P < 0.01,
Fig 6B; 55.38  3.80 cells/field vs. 16.43  3.34 cells/field,
P < 0.01, Fig EV4C), while DP1 deletion had inhibited proliferation of
epithelial cells as measured by the Ki-67 immunoreactivity (P < 0.05,
Fig 6C). Similarly, in primary cultured epithelial cells, DP1 deficiency
augmented IL-13-induced epithelial apoptosis (39.65  0.52% vs.
27.46  0.55%, P < 0.01, Fig 6D). Interestingly, niacin protected
colonic epithelial cells against DSS-induced apoptosis and promoted
cell proliferation in WT mice, but not in DP1-deficient mice (Fig 6E–
F). Thus, niacin helps maintain the intestinal epithelium barrier by
activation of the DP1 receptor.
◀ Figure 4. DSS-induced colitis in endothelial cell, epithelial cell, macrophage, or smooth muscle cell-specific DP1-deficient mice.A, B DP1 receptor expression in post-operative colon tissues from UC patients (A) and inflamed colons from DSS-challenged wild-type mice (B). The arrows indicate
DP1+ cells. Scale bars: 100 lm.
C DP1 expression in endothelial cells (EC), colonic epithelial cell (EPC), peritoneal macrophages (PM), and smooth muscle cells (SMC) in tissue-specific DP1-deficient
mice.
D, E Body weight loss (D) and disease activity index (E) of DP1F/F/Tie2Cre mice, DP1F/F/VillinCre mice, DP1F/F/LysMCre mice, and DP1F/F/SM22Cre mice in response to DSS
administration.
F Macroscopic appearance of representative colons from DSS-challenged DP1F/F/Tie2Cre mice, DP1F/F/VillinCre mice, DP1F/F/LysMCre mice, and DP1F/F/SM22Cre mice
(upper) and quantitation of colon length (bottom). Scale bar: 1 cm.
Data information: (C–F) Data are shown as mean  SEM. Results are representative of two independent experiments. Statistical significance was determined using
unpaired Student’s t-tests (C) and two-way ANOVA followed by a Bonferroni post hoc test (D–F). (C) *P < 0.01; n = 6. (D–F) **P < 0.01 vs. DP1F/F; DP1F/F,
DP1F/F/SM22Cre, n = 8; DP1F/F/Tie2Cre, DP1F/F/VillinCre, DP1F/F/LysMCre, n = 7.
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Niacin depresses intestinal inflammatory reaction by promoting
M2 polarization in experimental colitis in mice
Recently, we found DP1 deficiency in macrophages led to M1 polar-
ization and delayed resolution in zymosan-induced peritonitis in
mice (Kong et al, 2016, 2017), and deletion of the DP1 receptor in
macrophages (DP1F/F/LysMCre) aggravated DSS-induced colitis
(Fig 4D–F). We hypothesize that activation of the DP1 receptor in
macrophages (i.e., niacin intake) may reduce intestinal inflamma-
tion by directing macrophage polarization toward anti-inflammatory
M2-like cells. As shown in Figs 7A and B and EV4D, disruption of
the DP1 receptor in macrophages decreased the proportion of M2-
like macrophages (CD301+CD68+ or CD206+F4/80+) infiltrated in
inflamed intestines in both DSS- and TNBS-challenged mice. Consis-
tent with this finding, in intestinal macrophages separated by flow
cytometry (Fig 7C), the expression of pro-inflammatory genes
[tumor necrosis factor-a (TNF-a), MCP-1] is markedly induced and
expression of anti-inflammatory genes (IL-4, IL-5, and IL-10) is
suppressed by DP1 deficiency (Fig 7D). Interestingly, some
inflammatory genes, such as IL-1b and TGF-b, displayed extremely
reduced expression in intestinal macrophages (data not shown). We
also examined whether niacin may delay DSS-induced colitis
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Figure 5. Niacin inhibits DSS-induced vascular permeability.
A H&E staining of distal colons from DSS-challenged DP1F/F/Tie2Cre and DP1F/F mice. Scale bar: 100 lm.
B Representative images of Evan’s blue extravasation in ears from DP1F/F/Tie2Cre and DP1F/F mice. Dye leakage is induced by LPS after 30 min in BW245C or vehicle
pre-treated mice.
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E Effect of niacin on Evan’s blue extravasation in the colonic mucosa from DP1/ and WT mice. Mice were sacrificed at day 6 or day 9 as indicated. n = 6.
Data information: (C–E) Representative data are shown as mean  SEM derived from two independent experiments. Statistical significance was determined using
unpaired Student’s t-tests. ##P < 0.01 vs. vehicle, **P < 0.01 as indicated.
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partially through modulation of macrophage polarization. Indeed,
niacin facilitated intestinal macrophage polarization toward M2
status by increasing CD301+CD68+ cell ratio in DSS-challenged
intestines (Fig 7E), downregulating pro-inflammatory genes, and
provoking anti-inflammatory gene expression (Fig 7F). However,
the phenotypic turnover of macrophage by niacin was not observed
in myeloid DP1-deficient mice, suggesting DP1 receptor mediates
the M2 polarization elicited by niacin (Fig 7G).
PGD2 infusion ameliorates DSS-induced colitis in mice
To further confirm that niacin relieves UC through releasing PGD2
in mice, we directly infused PGD2 to DSS-challenged mice. As
shown in Fig EV5A–C, PGD2 ameliorates DSS-induced colitis in mice
as evidenced by decreased body weight loss, DAI, and shortening of
the colon after DSS challenge. As expected, PGD2 administration
significantly inhibited Evan’s blue extravasation in the inflamed
intestines at day 9 (0.13  0.01 lg/mg vs. 0.25  0.02 lg/mg,
P < 0.01, Fig EV5D), markedly decreased DSS-induced apoptosis of
epithelial cells (Fig EV5E), and increased the proportion of M2-like
macrophages (Fig EV5F).
Niacin induces clinical remission in patients with moderately
active UC
We investigated whether niacin induced clinical remission in
patients with moderately active UC. Twenty-six UC patients
(Dubinsky et al, 2003; Annese et al, 2005), who did not respond
to conventional therapies, were recruited. Demographics and base-
line characteristics of patients are summarized in Appendix
Table S1. Patients were assigned to receive retention enema treat-
ment (including 300 mg niacin/100 ml) daily for 6 weeks (Fig 8A).
As we expected, PGD2 production as measured by urinary tetranor
PGDM was elevated in patients after niacin administration
(Fig 8B). PGF2a production was also increased by niacin treatment
without any influence on urinary 8-isoprostane PGF2a
(Appendix Fig S2A and B). Surprisingly, the proportion of patients
with clinical response was 92.3% (24/26), and the proportion of
clinical remissions was 88.5% (23/26). Compared to baseline, 23
out of 26 patients achieved mucosal healing (Fig 8C). Patients
receiving niacin treatment had significant improvement in the
Mayo score (Fig 8D). Each subscore, such as stool frequency,
rectal bleeding, endoscopic findings, or physician’s global assess-
ment, is reduced significantly after niacin treatment (Appendix
Table S2). Moreover, 24 out of 26 patients that received niacin
treatment underwent overall histological improvement with normal
epithelium, mucosal architecture, and lamina propia cellularity
and few inflammatory cell infiltration (Fig 8E). C-reactive protein
(CRP) and erythrocyte sedimentation rate (ESR) levels in plasma
and platelet activities of UC patients were not markedly altered
after niacin treatment (data not shown). No serious adverse effect
of niacin, including flushing and urticaria, was observed
(Appendix Table S3). And niacin retention enema did not influ-
ence lipid profile of patients (Appendix Table S4). Overall, enema
treatment in combination with niacin is well tolerated and effective
in inducing clinical remission in UC patients.
Figure 6. DP1 receptor contributes to the protection of niacin against DSS-induced epithelial cell apoptosis.
A H&E staining on distal colons from DSS-challenged DP1F/F/VillinCre and DP1F/F mice. Scale bars: 100 lm.
B TUNEL assay (left) and quantitation (right) in colonic tissues from DP1F/F/VillinCre and DP1F/F mice. The arrows indicate the TUNEL+ cells (left). The arrows indicate
the TUNEL+ cells. Scale bars: 100 lm. DP1F/F, n = 5; DP1F/F/VillinCre, n = 4.
C Representative Ki67 staining (upper) and quantitation (bottom) of Ki67 in colonic tissues from DP1F/F/VillinCre and DP1F/F mice. Anti-pan-keratin (PK) antibody and
anti-Ki67 antibody were used. Scale bars: 100 lm. n = 4.
D Representative flowcharts (left) and quantitation (right) of Annexin V-positive IL-13-treated colonic epithelial cells from DP1F/F/VillinCre and DP1F/F mice. n = 3.
E, F Effect of niacin on DSS-induced epithelial cell apoptosis and proliferation inhibition in DP1/ and WT mice. The arrows indicate the TUNEL+ cells. Scale bars:
100 lm. n = 4.
Data information: Data are expressed as mean  SEM. Statistical analysis was performed using unpaired Student’s t-test. All data were verified in two independent
experiments. (B, C) *P < 0.05, **P < 0.01 vs. DP1F/F. (D) #P < 0.05, ##P < 0.01 compared with vehicle, **P < 0.01, as indicated. (E, F) ##P < 0.01 compared with vehicle,
**P < 0.01, as indicated.
▸Figure 7. Niacin suppresses pro-inflammatory cytokine expression in macrophages in DSS-induced colitis in mice.A Representative immunofluorescent staining (left) and quantitation (right) of CD301+CD68+ cells in colonic tissues from DSS-challenged DP1F/F/LysMCre and DP1F/F
mice. The arrows indicate the CD301+CD68+ cells (left panel). Scale bar: 100 lm. n = 4.
B Flow cytometry analysis of CD206+F4/80+ cells in colons DSS-challenged DP1F/F/LysMCre and DP1F/F mice. n = 5.
C Flow cytometry analysis of CD11b+F4/80+ cells in colons from DSS-challenged mice.
D Real-time PCR analysis of TNF-a, MCP-1, IL-4, IL-5, and IL-10 expression in colonic F4/80+CD11b+ cells in DP1F/F/LysMCre mice and DP1F/F mice. n = 6.
E Effect of niacin on colonic macrophage infiltration in DSS-challenged DP1/ and WT mice. The arrows indicate the CD301+CD68+ cells. Scale bar: 100 lm.
WT-vehicle, DP1/-vehicle, DP1/-niacin: n = 4; WT-niacin, n = 7.
F Effect of niacin on MCP-1, IL-5, and IL-10 expression in colonic F4/80+CD11b+ cells in DP1/ mice and WT mice. n = 6.
G Schematic illustration of the protective mechanisms of PGD2/DP1 axis in UC. Niacin stimulates PGD2 release in the inflamed colon tissues, which inhibits vascular
permeability, suppresses DSS-induced apoptosis, and downregulates pro-inflammatory cytokine secretion in macrophages through activation of DP1 receptor.
IECs, intestinal epithelial cells; SMCs, smooth muscle cells; MΦ: macrophage.
Data information: All data are expressed as mean  SEM. P-values were calculated using unpaired Student’s t-test. Data are representative of at least two independent
experiments. (A, B) **P < 0.01 vs. DP1F/F. (D) *P < 0.05 vs. DP1F/F. (E) ##P < 0.01 vs. vehicle, **P < 0.01 as indicated. (F) #P < 0.05 vs. vehicle, *P < 0.05, **P < 0.01 as
indicated.
◀
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Discussion
Ulcerative colitis is a chronic, relapsing inflammatory bowel
disease, and the pathological changes of the colonic tissues
affected include crypt branching, irregularity of size and shape of
crypt, inflammatory cell infiltration in the lamina propia, and even
erosion (Danese & Fiocchi, 2011). In this study, we demonstrated
that niacin displayed multifaceted protective effects against DSS/
TNBS-induced colitis in mice through activation of the DP1 recep-
tor, including inhibition of vascular leakage, suppression of
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Figure 8. The therapeutic effect of niacin retention enema on patients with moderately active UC.
A Clinical study design of niacin retention enema therapy. MDS: metronidazole, dexamethasone, starch.
B Effect of niacin retention enema on urinary tetranor PGDM production in patients.
C Representative endoscopic images of colon mucosa from patients involved in this study. Superficial ulceration, granulocyte infiltration, and distorted/branching crypts
are apparent in biopsies from patients with active disease, whereas those from the healthy subjects or those in remission appear normal.
D Changes of Mayo score of UC patients before and after niacin retention enema therapy.
E Representative H&E staining colon mucosa from UC patients. Scale bar: 100 lm.
Data information: P-values were calculated using paired Student’s t-test. (B) *P < 0.05 as indicated, n = 8. (D) **P < 0.01 as indicated, n = 26.
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colonic epithelium apoptosis, and reduction of pro-inflammatory
cytokine secretion. These disorders interactively promote patholog-
ical progression of UC (Su et al, 2009; Khor et al, 2011). Retention
enema with niacin facilitated mucosal healing in patients with
moderately active UC.
Prostaglandins are synthesized from arachidonic acid through
the action of phospholipases and cyclooxygenases and are involved
in many inflammatory processes (Zhang et al, 2010; Fattahi &
Mirshafiey, 2012; Dennis & Norris, 2015; Cheng et al, 2016). Non-
steroidal anti-inflammatory drugs (NSAID), which are widely
utilized as analgesic and anti-inflammatory agents for the treatment
of arthritis and other inflammatory disorders, have been reported to
exacerbate IBD (Felder et al, 2000; Bonner, 2001; Matuk et al,
2004). Mice lacking either COX-1 or COX-2 show increased sensitiv-
ity to DSS, and inducible COX-2-deficient mice are more susceptible
than COX-1-deficient mice (Morteau et al, 2000). COX-2 expression
in myeloid cells and endothelial cells confers protection against
DSS-induced colitis (Ishikawa et al, 2011). Indeed, PGD2 is impor-
tant for induction and maintenance of UC remission in both rodents
and humans (Ajuebor et al, 2000; Vong et al, 2010). Consistent with
this function, blockade of PGD2 downstream receptor DP1 worsens
DSS-induced colitis in mice (Cheng et al, 2006; Sturm et al, 2014).
We found that niacin induces remission of UC in mice via DP1.
Moreover, DP1 receptor expression in vascular endothelial cells,
colonic epithelium, and myeloid cells is critical to protect the
colonic mucosa from injury in DSS/TNBS-induced colitis mouse
models. These observations suggest that PGD2 derived from COX
enzymes (mostly COX-2) and perhaps PGE2 (Tessner et al, 1998;
Tanaka et al, 2009) are responsible for NSAID-exacerbated colitis.
However, we failed to detect a significant effect of DP2 knockout on
DSS-induced colitis in mice, which does not seem to match the
observations obtained from pharmacological inhibition of the DP2
receptor (Sturm et al, 2014).
Niacin reduces plasma levels of free fatty acids and cholesterol
through activation of GPR109A receptor on adipocytes while caus-
ing an unwanted facial flushing side effect due to the GPR109A-
mediated PGD2 release on Langerhans cells and keratinocytes
(Benyo et al, 2006; Maciejewski-Lenoir et al, 2006; Hanson et al,
2010). Besides adipose tissue and immune cells (Feingold et al,
2014), GPR109A receptor is also expressed in colonic epithelium
(Ganapathy et al, 2013). Indeed, PGD2 production was induced by
niacin treatment in colon tissues. The disruption of DP1 receptor
augmented inflammatory response by increasing pro-inflammatory
cytokine expression, enhanced apoptosis in colonic epithelium, and
vascular permeability in DSS- or TNBS-challenged mice. Thus,
niacin ameliorated DSS/TNBS-induced colitis by inhibition of
colonic epithelium apoptosis and of inflammatory reactions in the
lamina propia. In agreement with our results, niacin has been found
to display anti-inflammatory properties in other inflammatory
diseases such as coronary artery disease (Kuvin et al, 2006) and
atherosclerosis (Yu & Zhao, 2007). In addition, the activation of
GPR109A in myeloid cells induces IL-10 expression and subsequent
differentiation of regulatory T cells (Treg cells) and IL-10-producing
T cells (Singh et al, 2014). IL-10 secretion was dramatically reduced
in DP1-deficient myeloid cells in DSS-induced colitis mice, strongly
indicating that the niacin/GPR109A axis-mediated anti-inflamma-
tory IL-10 secretion may depend on PGD2/DP1 signaling in myeloid
cells.
Retention enema in combination with niacin induces clinical
remission and endoscopic mucosal healing of the eligible patients
with moderately active UC (limited to the left half of the colon and
rectum). It is an explorative and self-controlled follow-up study.
However, there are several limitations of this clinical study, such as
small sample size, lack of placebo control, relatively short period of
medication, short follow-up period, and the fact that all the
recruited patients are unresponsive to conventional treatment.
Moreover, it remains to be investigated whether oral intake of
niacin would have an equivalent effect on UC as the retention
enema.
In summary, we demonstrated that niacin treatment ameliorates
UC by boosting PGD2 release in both mice and patients, indicating
niacin may serve as an effective therapeutic option for UC patients,
especially those with an inadequate or no response to conventional
treatment.
Materials and Methods
Mice
VillinCre mice were purchased from Model Animal Research
Center of Nanjing University, and EllaCre, Tie2Cre, LysMCre, and
SM22Cre mice were obtained from Jackson Laboratory (Bar
Harbor, Maine, USA). All the colonies including DP1 (Kong et al,
2016) and DP2 (Satoh et al, 2006) mutants were maintained on a
C57BL/6 genetic background. DP1Flox/Flox (DP1F/F) mice were
crossed with Tie2Cre, VillinCre, LysMCre, or SM22Cre transgenic
mice to generate cell-specific DP1-deficient mice, respectively.
Animals were maintained and experiments were carried out with
the approval of the Institutional Animal Care and Use Committee
of the Institute for Nutritional Sciences, Chinese Academy of
Sciences.
Reagents
Dextran sulfate sodium (DSS) was purchased from MP Biomedicals
(LLC, Santa Ana, California, USA). TNBS, LPS, Evan’s blue, and
niacin were purchased from Sigma Chemical Company (Sigma-
Aldrich, St. Louis, MO, USA). PGD2 and BW245C were obtained
from Cayman Chemical Company (Cayman Chemical, Ann Arbor,
MI, USA). Percoll solution was from Biosharp (Biosharp, Hefei,
China). IL-13 was purchased from Peprotech (Peprotech, Rocky Hill,
USA). TdT fluorescence in situ Apoptosis Detection kit was from
Yeasen Biological Technology (Yeasen, Shanghai, China). Annexin
V-FITC Apoptosis Detection Assay kit was obtained from Dojindo
Laboratories (Dojindo, Shanghai, China).
Induction of mouse colitis
For DSS-induced colitis, 6- to 8-week-old male mice were subjected
DSS administration (molecular weight: 36,000–50,000 D) through
drinking water (2%) for 6–9 days as indicated. As for TNBS-induced
colitis, 6- to 8-week-old male mice were pre-sensitized with 1%
TNBS at day 1 and then challenged with 2.5 % TNBS (100 ll)
intrarectally at day 8 (Wirtz et al, 2007). Niacin was used to treat
mice by gavage at a dose of 600 mg/kg/day, which is comparable to
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the therapeutic dose used in dyslipidemic patients if the 10 times
faster metabolism of mice as compared to humans is taken into
account (van der Hoorn et al, 2008). Body weight was measured
every day from the beginning of the DSS and TNBS administration.
The body weight loss was calculated as the percentage change
compared to the original body weight. The stool consistency and
gross bleeding were monitored daily. The disease activity index
(DAI) was calculated by the combined scores of the following
parameters divided by 3: weight loss (0, normal; 1, 0–5%; 2, 5–
10%; 3, 10–20%; 4, > 20%), stool consistency (0, normal; 2, loose
stools; 4, watery/diarrhea), and gross bleeding in stool (0, negative;
2, positive in hemoculture; 4, macroscopic hematochezia) (Cooper
et al, 1993).
Primary cell culture
For preparation of peritoneal macrophages, mice were injected
intraperitoneally with 1 ml of 10% thioglycollate medium
(Scharlau, Barcelona, Spain). On the fourth day, the mice were
euthanized and injected intraperitoneally with 7–8 ml of ice-cold
phosphate-buffered saline (PBS), and then peritoneal macrophages
were collected and cultured in Roswell Park Memorial Institute
(RPMI) 1,640 medium with 10% fetal bovine serum at 37°C, 5%
CO2 (Wang et al, 2014).
For preparation of colonic epithelial cells and lamina propria
mononuclear cells (LPMCs), intestine biopsies were opened longitu-
dinally and cut into 1-cm pieces. They were incubated in 5 ml pre-
digestion solution Hanks’ balanced salt solution (HBSS) containing
5 mM ethylenediaminetetraacetic acid (EDTA) and 1 mM dithio-
threitol (DTT) for 1 h at 37°C, and the intestine pieces were
subjected to 100-lm cell strainer to get single primary cells. The
cells were further centrifuged with a 50% Percoll solution at 500 g
for 20 min, and the epithelial cells were then equilibrated at the
interface (Evans et al, 1992).
For preparation of intestinal LPMCs, intestine biopsies were cut
into 1-mm pieces and incubated in a digestion solution containing
0.05 g of collagenase D (Roche, Basel, Switzerland), 0.05 g of
DNase I (Sigma-Aldrich, St. Louis, MO, USA), and 0.3 g of dispase II
(Roche) for about 40 min until all the pieces were fully digested.
The cell pellets were obtained after centrifugation at 500 g for
10 min, followed by resuspension and separation in 40%/80%
Percoll solution by centrifugation at 1,000 g for 20 min, and LPMCs
could be visible as a white ring at the interface (Weigmann et al,
2007).
Vascular smooth muscle cells and endothelial cells were
prepared from aortas and lungs as previously reported (Zhang et al,
2013; Lu et al, 2015), respectively. Vascular endothelial cells at 2–3
passages were used for experiments.
Flow cytometry
The lamina propia mononuclear cells were stained with fluores-
cence-tagged primary antibodies (Brilliant Violet 421-F4/80, Biole-
gend, San Diego, CA, USA; FITC-anti-CD11b, MACS, Bergisch
Gladbach, Germany, FITC-anti-CD206, Biolegend, San Diego, CA,
USA) for 45 min at 4°C. Flow cytometry was performed using a
BD LSRFortessaTM cell analyzer (BD Biosciences, San Jose, CA,
USA).
Hematoxylin and eosin and Immunofluorescence staining
For hematoxylin and eosin (H&E) staining, mouse colon tissues
were fixed in 4% paraformaldehyde and embedded in paraffin and
then incised a 4-lm section. The sections were stained with both
hematoxylin and eosin, and then photographed using an electron
microscope.
For immunofluorescence staining, colon biopsies from UC
patients and mice were embedded in O.C.T. compound (Tissue Tek,
Sakura, Torrance, CA, USA), and then incised 8-lm sections and
processed for immunostaining. The DP1 expression was examined
with polyclonal anti-DP1 primary antibody (Cayman Chemical, Ann
Arbor, MI, USA). The endothelial cells were marked with anti-CD31
(1:200, BD Biosciences, San Diego, CA, USA). To detect epithelial
cell and macrophage, anti-pan-keratin-FITC antibody (Cell Signaling
Technology, Danvers, MA, USA) and anti-CD68 (1:200, AbD
Serotec, Kidlington, UK) primary antibody were used. To label the
smooth muscle cells, the anti-a-actin-FITC antibody (1:200, Sigma-
Aldrich, St. Louis, MO, USA) was used. Anti-CD301 (1:100 Bio-Rad,
California, USA) primary antibody was used to mark M2-like macro-
phage, and anti-Ki67 (1:500, Epitomics, Burlingame, CA, USA)
primary antibody was used to label proliferating cell.
Mouse genotyping
Genomic DNA from mouse tail biopsies was extracted as template.
PCR products were resolved by electrophoresis in a 2% agarose gel
(Biowest, Verkiu, Lithuania), and stained with ethidium bromide.
The images were digitally captured with a SynGene gel image
system (Tanon 2500, Shanghai, China). The primers used in this
study are shown in Appendix Table S5.
RNA preparation and RT–PCR analysis
Total RNA was isolated with TRIzol reagent (Invitrogen, San Diego,
CA, USA). The reverse transcription reactions were performed by
use of Reverse Transcription Reagent kits (Takara, Otsu, Shiga,
Japan). Real-time PCR was conducted with SYBR Green mix
(Applied Biosystems, CA, USA). The primers used in this study are
summarized in Appendix Table S5.
Vascular permeability assay
After anesthesia, both ears of one group of mouse were injected
intradermally with 3 mg/kg (in 10 ll) BW245C and the ears of
the other group were injected with vehicle. After 30 min, 10 ll
(1 mg/ml) LPS was injected in the left ear of all mice, whereas
only PBS was injected on the right ear. 30 min later, mice
received 100 ll of 1% Evan’s blue in PBS through tail vein injec-
tion. All animals were euthanized after 15 min by CO2 inhalation.
Ear biopsies were collected with a 6-mm Acu-Punch, (Acuderm
Inc., Ft. Lauderdale, FL, USA) and immersed in 1 ml of forma-
mide overnight in a water bath at 55°C. Evan’s blue dye was
extracted from ear biopsies and measured by absorbance at
610 nm using a spectrophotometer.
For vascular permeability in DSS-induced UC, mice with DSS-
induced colitis received intravenously 100 ll of 1% Evan’s blue
in PBS 15 min before being sacrificed. After autopsy, the colon
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tissues were dried and weighed. Evan’s blue was extracted and
quantitated.
Apoptosis analysis
For terminal deoxynucleotidyl transferase (TdT)-mediated biotin-16-
dUTP nick-end labeling (TUNEL) assay, the colon tissues from mice
with DSS administration were imbedded in O.C.T. compound and
made into 8-lm frozen sections. The frozen sections were stained
with a TUNEL fluorescence in situ Apoptosis Detection kit (Yeasen,
Shanghai, China) according to the manufacturer’s manual.
For Annexin V-FITC Apoptosis Detection, after treatment with
IL-13 or vehicle, the adherent primary epithelial cells were prepared
and stained with Annexin V-FITC Apoptosis Detection kit according
to the manufacturer’s instructions. Annexin V binding was analyzed
by flow cytometry within 1 h.
Mass spectral analysis
Urinary prostanoid metabolites, 8-isoprostane prostaglandin F2a,
were extracted and quantitated as previously reported (Zhang et al,
2013). In brief, mouse urine was collected for 12 h in metabolic
cages after niacin treatment. Samples (100 ll) were spiked with
internal standards [tetranor PGDM-d6, tetranor PGEM-d6, 13,14-
dihydro-15-keto-PGF2a (PGFM)-d4, 2,3-dinor-6-keto PGF1a (PGIM)-
d4, 11-dehydro-thromboxane B2 (TxM)-d4, and 8-iso-PGF2a-d4,
(5 ll)] contained in acetonitrile (ACN). 200 ll methoxy-amine HCl
(1 g/ml), an aqueous solution, was added. After standing for
30 min at room temperature, make capacity to 1 ml by water. The
samples were applied to the cartridge conditioned with 1 ml of
acetonitrile and equilibrated with 1 ml of water. After being washed
with 1 ml of 5% acetonitrile in water, they were dried with vacuum
for 15 min. After being subjected to elution using 1 ml of 5%
acetonitrile in ethyl acetate, the samples were dissolved in 100 ll
10% ACN in water and passed through small centrifugal filters with
a 0.2-lm nylon membrane prior to analysis by mass spectrometry.
The urinary creatinine was used to normalize the prostaglandin
metabolites, 8-isoprostane prostaglandin F2a.
Colon tissues from mice were homogenated and centrifuged and
500 ll of supernatant was collected for PG and SPM production
analysis. In brief, internal standards (PGD2-d4, 6-keto-PGF1a-d4,
PGF2a-d4, PGE2-d4, TxB2-d4, RvD1-d5, RvE1-d5, 8-iso-PGF2a-d4
and 5(S)6(R)-LXA4-d5 (5 ll)) were added to the samples in 40 ll of
citric acid (1 M) and 5 ll of 10% butylated hydroxytoluene, and
then the samples were vigorously vortexed with 1 ml solvent
(normal hexane:ethyl acetate, 1:1). The organic phase supernatant
was collected after centrifugation (6,000 g, 10 min). After being
subjected to elution using 1 ml of 5% acetonitrile in ethyl acetate,
the samples were dissolved in 100 ll 10% ACN in water and passed
through small centrifugal filters with a 0.2-lm nylon membrane
prior to analysis by mass spectrometry. PG and SPM production was
normalized to total protein of extracted tissues.
Plasma lipid measurements
Plasma triglyceride (TG), total cholesterol (TC), low-density lipopro-
tein (LDL), and high-density lipoprotein (HDL) levels were
measured using commercial kits (Jiancheng, Nanjing, China).
Clinical study design and patients
This study was conducted to evaluate niacin as an effective alterna-
tive therapeutic agent for patients with UC unresponsive to conven-
tional treatment. All patients were recruited from the Department of
Gastroenterology of Ruijin Hospital in Shanghai Jiao Tong Univer-
sity School of Medicine from March 2015 to December 2016. The
trial is registered with Chinese Clinical Trial Registry (ChiCTR;
www.chictr.org.cn; ChiCTR-IOR-15006400). Eligible patients were
18 years old or above and had a diagnosis of moderately active left-
sided UC, including the descending colon, the sigmoid colon, and
rectum with a Mayo Clinic score greater than or equal to 6, a rectal
bleeding subscore of 1 or higher, and endoscopic subscore of 2 or
higher. Additional inclusion criteria were documentation of inade-
quate or no response to conventional retention enema treatment
(5-aminosalicylate, metronidazole, dexamethasone, starch) and
regular oral medicines in the past 1–2 years, such as 5-aminosalicy-
late (5-ASA) and/or corticosteroids. Briefly, eligible patients had no
clinical response to following sequential therapies according to clini-
cal practice guidelines for the medical management of ulcerative
colitis within 6 months before the study (Mowat et al, 2011;
Bressler et al, 2015): (i) oral 5-aminosalicylate (5-ASA, 4 g of
Pentasa per day) induction therapy for 8 weeks; (ii) oral corticos-
teroids (30–40 mg of oral prednisolone or the equivalent per day)
for 4 weeks; and (iii) oral 5-aminosalicylate (5-ASA, 4 g of Pentasa
per day) with consecutive regular retention enema treatment (5 mg
of dexamethasone, 0.5 g of metronidazole, and 5 g of starch in
100 ml saline per day) for 6 weeks. Patients were excluded if they
had extremely severe UC, severe colonic stricture, infectious enteri-
tis, a history of bowel surgery, major organ dysfunction, malignant
neoplasm, pregnancy, hypertension, diabetes, and concomitant use
of immunosuppressants such as azathioprine (AZA), mercaptop-
urine (MP), anti-TNF therapy. The study was reviewed and
approved by the Ruijin Hospital Ethics Committee of Shanghai Jiao
Tong University School of Medicine, and conducted in accordance
with the Good Clinical Practice, the Belmont report, the Declaration
of Helsinki, and other relevant rules and regulations. All patients
provided written informed consent.
Clinical study protocol
In the study, eligible patients received retention enema treatment
with niacin (0.5 g metronidazole, 5 mg dexamethasone, 5 g starch,
300 mg niacin in 100 ml saline) daily for 6 weeks, who continued
to take oral 5-aminosalicylate (4 g of Pentasa per day) throughout
the study. The patients were examined at the beginning and the 6th
week. Mayo Clinic scores were calculated, colonoscopy was
performed with biopsy, and blood samples were collected for hema-
tologic testing. In addition, the urine samples were obtained at 0
and 4 h after retention enema treatment for PG metabolite measure-
ment. The primary endpoint was a clinical response, defined by a
decrease in the Mayo Clinic score ≥ 3 points and ≥ 30% from the
baseline score, with a decrease ≥ 1 point from the baseline score on
the rectal bleeding subscore or a rectal bleeding subscore of 0 or 1.
Clinical remission was defined as a Mayo Clinic score of 2 or lower
with no subscore > 1. Mucosal healing was defined as an endo-
scopic subscore of 0 or 1 as assessed by a professional endoscopist
(Yoshimura et al, 2015).
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Statistical analysis
All data are expressed as the mean  standard error of the mean
(SEM). Data were analyzed using GraphPad Prism software, version
5.0 (GraphPad Software, San Diego, CA, USA). The two-tailed
unpaired Student’s t-test was performed to compare the two data-
sets. Multiple comparisons were tested with two-way ANOVA
followed by Bonferroni’s post-test. A P-value of less than 0.05 was
considered statistically significant. For the clinical trial, paired
Student’s t-test was used to compare the values before and after
niacin treatment. The exact P-values in each figure are listed in
Appendix Table S6.
Expanded View for this article is available online.
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